Researchers have discovered a protein, RAR1, critical for response to retinoid treatment, which is resistant to this class of drugs. By triggering RAR1 protein expression in cancer cells, sensitivity can be restored, offering new hope for lung cancer patients.
Researchers will focus on understanding human stem cells, transplanting them into patients for leukemia and lymphoma treatment, and using natural killer cells to fight cancer. The funding also aims to apply what has been learned about the use of natural killer cells in fighting diseases including leukemia and breast cancer.
The research discovered the structure of JAK2 kinase, a well-validated drug target for cancer and other disorders. The discovery will enable the development of specific molecules to treat diseases where JAK kinases play a pivotal role, leading to a rapid growth of phase I therapeutics.
Researchers at VCU Massey Cancer Center discovered a new agent, Bay 43-9006, that targets the Mcl-1 protein to inhibit leukemia cell survival. The study found that Bay 43-9006 reduces Mcl-1 levels through an unusual mechanism, inhibiting protein synthesis.
Researchers at the University of Toronto have identified a key component blocking stem cell growth and developed a system to expand cord blood stem cells, potentially treating adult patients with leukemia. The discovery may lead to clinical trials within the next year.
Researchers identified distinct genetic signatures and cancer stem cell populations driving different subtypes of ependymomas. These findings suggest individualized treatment approaches targeting specific cancer stem cell populations could improve outcomes for patients with these tumors.
Researchers at the University of Minnesota have successfully generated natural killer cells from human embryonic stem cells that can target and destroy cancer cells. The breakthrough research suggests a potential new approach to treating cancers such as leukemia and lymphoma, and may also lead to treatments for infections.
Researchers discovered that KLF2 regulates embryonic globin genes and maturation of red blood cells in a mouse model, potentially paving the way for future gene therapies. The study highlights the importance of understanding gene regulation in blood disorders like sickle cell anemia and beta-thalassemia.
A new study shows that hydroxyurea is an efficient and safe treatment option for young children with sickle cell anemia, improving spleen function and reducing acute chest syndrome incidents
Researchers identified a new gene, BRIP1, associated with Fanconi anemia's hallmark chromosomal instability. The protein BACH1 helps DNA unwind for repair, and BRIP1 mutations disrupt this process.
A large study found that young children with medulloblastoma are at risk of impaired reading skills after radiation therapy, even if they receive lower doses. The greatest decline in IQ and reading skills occurred in patients younger than 7 years old.
Researchers found that the revised TNM staging system is strongly associated with disease-free survival and overall survival. The new system provides more accurate information about tumor response to chemotherapy, helping doctors determine the best treatment plan for patients.
Researchers discovered that Arf gene restricts blood vessel growth in the eye during embryonic development, preventing excessive growth and associated cancers. This finding may lead to new therapies for persistent hyperplastic primary vitreous and anticancer drugs.
Researchers identify NF-Ya as a master-regulatory gene controlling stem-cell division programs. Overexpressing NF-Ya increases stem cell production by ten- to twenty-fold.
Researchers at University of Cincinnati have developed a new chemical compound that can accelerate adult stem cell mobilization, enabling easier harvesting. The findings reveal the RAC GTPase family plays a crucial role in regulating stem cells' movement into bone marrow and blood stream.
Researchers found that NIPA levels act as a switch to regulate cell division by degrading cyclin B1 during the 'resting' phase. Blocking NIPA causes premature cell division, leading to unhealthy daughter cells. The study sheds light on the role of SCFNIPA in controlling mitosis.
A Phase 2 study of Aranesp(R) demonstrates a 77% overall response rate in low-risk MDS patients with anemia. Patients who had never received erythropoietic therapy responded well to Aranesp, while those with prior treatment showed continued efficacy.
Christine Chung, a Vanderbilt researcher, has won the Damon Runyon Research Foundation/Lilly Clinical Investigator Award to support her work on genetic profiling for head and neck cancers. The award will provide funding for DNA microarray technology to predict tumor recurrence and response to chemotherapies.
A large study comparing thalidomide and traditional chemotherapy in multiple myeloma patients found that thalidomide was more effective, with 76% of patients achieving at least partial remission. The treatment also had fewer side effects, particularly deep vein thrombosis compared to granulocytopenia.
Abed-rest study investigates the impact of space-like conditions on the human immune system, exploring possible causes of a compromised immune response. The study aims to provide valuable data for international efforts to plan long-duration missions and address health risks associated with chronic radiation exposure.
A 14-month study found that dexmethyphenidate (d-MPH) significantly reduced fatigue and improved memory in cancer survivors with chemobrain. The medication, taken at dosages of 10-50 mg per day, showed safe and effective results for relieving chemobrain symptoms.
Researchers identified genetic variations associated with treatment resistance in childhood ALL, highlighting potential for personalized chemotherapy and simplified diagnostic tests. The study found links between specific gene variants and hematological relapse and central nervous system (CNS) cancer recurrence.
Patients who survived at least two years post-transplant showed reduced risk of death each year after the fifth anniversary. Mortality not related to relapse was increased in patients with specific chemotherapy regimens and stem cell sources.
Researchers used disabled retroviruses to discover genes that increase the multiplication rate of stem cells, which could improve regenerative medicine. The study found that these genes can be used to enhance the fitness of stem cells, potentially leading to new treatments for inherited blood disorders.
A landmark Phase III trial found that concurrent chemotherapy and radiation therapy followed by surgery significantly improves lung cancer patient survival. Five-year survival rates were 36% for patients with partial lung removal and 27% for those who underwent concurrent treatment.
A new study demonstrates high rates of tumor death in patients receiving a preoperative chemotherapy and radiation regimen, suggesting a promising approach for treating high-grade soft tissue sarcomas. The regimen has been associated with significant but manageable toxicity and modest wound complication rates.
Researchers analyzed tumor DNA from 324 GIST patients and found that those with a KIT exon 11 mutation responded better to Gleevec. The study confirms the need for new drugs for patients whose GIST genotype is less responsive to Gleevec.
The Research on Adverse Drug Events and Reports (RADAR) Project has identified serious adverse drug reactions with 14 commonly prescribed drugs and cardiac stents, affecting almost 1,700 patients. RADAR reviews have been published in leading medical journals and have helped save hundreds to thousands of patient lives.
Researchers at St. Jude Children's Research Hospital have developed a technique to produce large numbers of genetically modified NK cells that can effectively target and eliminate leukemia cells. The new technology has the potential to be used as a treatment for leukemia patients undergoing hematopoietic cell transplantation.
The study shows that blocking CK2 activity makes cancer cells sensitive to TRAIL-induced apoptosis, a promising strategy for treating colorectal cancer and other solid tumors. Researchers used a CK2-inhibitor or short hairpin RNA to block CK2 activity, sensitizing cancer cells to TRAIL and inducing cell death.
Recent research in chronic lymphocytic leukemia (CLL) identifies genetic and protein markers that can predict patient outcomes. These new markers may enable earlier treatment, improving survival rates and altering the disease's progression.
Researchers at Dana-Farber Cancer Institute have developed a new compound, AMN107, which targets Bcr-Abl kinase protein responsible for CML growth. In laboratory cell cultures and mice with the disease, AMN107 demonstrated effectiveness in killing CML cells and inducing longer remissions compared to Gleevec.
Researchers developed T cells targeting Epstein Barr virus antigens to treat advanced nasopharyngeal carcinoma. Six out of ten patients remained disease-free after treatment, with some experiencing partial remission.
Researchers using 'heavy water' tracked leukemia cell birth and death rates, revealing dynamic process with mortal cells that proliferate and die. The study found faster birth rates of leukemia cells correlate with poorer patient outcomes, paving the way for potential new methods of prediction and treatment guidance.
Tufts-NEMC researchers have discovered a key enzyme responsible for cancer cell growth and invasion, which can be blocked by new compounds called pepducins. The finding provides a novel therapeutic approach for treating invasive cancers.
Researchers genetically engineered zebrafish to develop black-pigmented moles with mutated human BRAF and p53 genes. The study shows that BRAF mutations are necessary for mole development, but insufficient for cancer. The model provides insights into how gene mutations contribute to melanoma
A new technique allows for successful cord blood transplants in high-risk acute and chronic leukemia patients, with disease-free survival rates of 57% at one year. The study's findings offer hope to thousands more patients who were previously ineligible due to lack of suitable donor units.
Researchers at City of Hope Cancer Center have successfully treated 17 out of 20 HIV-positive patients with refractory lymphoma using high-dose chemotherapy and autologous stem cell rescue. The study shows promising results with an 85% survival rate, paving the way for further investigation into this potential cure.
A Northwestern University study reveals potentially fatal blood clots in up to 20% of cancer patients treated with thalidomide. The drug's exclusive off-label use hinders information sharing about side effects.
The guidelines provide recommendations for screening and management of late effects in pediatric cancer survivors, aiming to improve adult quality of life. The report authors anticipate that widespread use will help researchers determine the efficacy of screening survivors to reduce medical complications and death.
A study found that cancer patients receiving long-term bisphosphonate therapy were at risk of developing jawbone necrosis, a condition that can lead to bone death and require surgery. The condition is often associated with tooth extractions or other major dental work while on the drugs.
A large phase III trial showed that sequential treatment with ELLENCE delivered superior disease-free and overall survival compared to FEC 100 alone. The sequential regimen resulted in a 17% reduction in relapse risk and a 23% reduction in mortality risk.
A new study by Loyola Medicine found that tamoxifen or other hormonal therapy alone may not be sufficient to treat hormone-dependent breast cancer. Chemotherapy proved more effective in stopping cancer recurrence, especially when combined with tamoxifen.
A combination of two biologic agents, alemtuzumab and rituximab, with chemotherapy has shown a promising response rate of 55% in CLL relapse patients. Complete remission was achieved by 23% of patients, while leukemia levels were reduced by at least half in 35% of cases.
A USC/Norris Comprehensive Cancer Center study reveals significant differences in survival rates between HIV-related lymphoma types, including DLCL and SNC. The research suggests that optimal therapy may differ for these sub-types of disease.
Researchers at Stanford University School of Medicine developed a technique to eliminate graft-versus-host disease without compromising cancer treatment. In clinical trials, the therapy showed promising results with only one patient developing severe graft-versus-host disease out of 37 treated patients.
Researchers found that a combination of thalidomide and dexamethasone is as effective as standard intravenous chemotherapy in treating newly diagnosed multiple myeloma. A newer analog, CC-5013 (lenalidomide), showed promise with fewer side effects.
New research presented at the American Society of Hematology Annual Meeting reveals promising results for tipifarnib, a potential treatment for acute myeloid leukemia (AML) in elderly patients. The study found molecular predictors of response to tipifarnib, offering hope for improved patient outcomes.
Researchers have developed a peptide vaccine that produces an immune response in 60% of patients with myeloid leukemia, resulting in complete molecular remission for three patients. The vaccine targets the PR1 peptide, which is overexpressed on leukemia cells, inducing immune T-cells to kill cancer cells while leaving normal cells intact.
New data from the largest study on CML patients (1106) showed improved rates of progression-free survival and durable responses to imatinib. Patients with early cytogenetic responses achieved higher progression-free survival rates, with 93% at 42 months compared to 74% without
The new compound BMS-354825 successfully overcomes Gleevec resistance in patients with chronic myeloid leukemia, showing an 85% success rate in phase I clinical trials. Researchers believe the drug's unique mechanism of action may provide a solution to this common problem.
Research from the Women's Interagency HIV Study found that HIV-infected women with low platelet counts had a five-fold increased risk of dying due to any cause. The study also revealed that highly active antiretroviral therapy, such as HAART containing zidovudine, can boost platelet counts back to normal.
Researchers have successfully demonstrated that half-matched donor (haploidentical) natural killer cells can survive and persist to actively attack cancer cells, potentially leading to remission and eligibility for bone marrow transplant. This breakthrough treatment option shows promise for some patients with AML.
Researchers have discovered that BMS-354825 and AMN107 can effectively treat patients with leukemia who are resistant to Gleevec therapy. The studies found remarkable activity in these novel compounds, with high response rates and improved survival outcomes.
The NHLBI halted a clinical trial on periodic blood transfusions for patients with sickle cell anemia due to the treatment's proven effectiveness in preventing strokes. However, the trial also highlighted potential long-term side effects such as iron overload and the need for ongoing monitoring.
A recent study has shown that children with sickle cell disease who are at risk for having a stroke need to continue receiving transfusions to minimize their risk. The study found that of the 41 children who came off transfusions, 14 reverted to high-risk status within 10 months and two others had strokes shortly after.
A new oral therapy, Zarnestra, has shown benefit in improving blood counts and preventing leukemia development in patients with myelodysplastic syndrome (MDS). The drug, a farnesyl transferase inhibitor, produces responses in about one-third of patients, offering hope for those at high-risk for developing acute myelogenous leukemia (AML).
Researchers tested a weakened version of herpes simplex virus against neuroblastoma tumors, with only the virus proving effective in treating the cancer. The study shows promise for using the therapy in children and potentially in other cancers as well.
Researchers at St. Jude Children's Research Hospital found that white matter lesions caused by treatment can mimic cancer, leading to unnecessary treatment. The study also linked WMLs to a decline in neurocognitive function in children with brain tumors.
Researchers found that patients' neuromotor functions, including problem-solving and motor skills, significantly declined after cancer treatment but recovered within a year. Factors such as chemotherapy type and immune suppressant use lowered the risk of impaired function.